Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023

Meningococcal disease is a life-threatening invasive infection caused by Neisseria meningitidis.Two quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccines (MenACWY) (MenACWY-CRM Menveo, GSK and MenACWY-TT MenQuadfi, Sanofi Pasteur) and two serogroup B meningococcal vaccines (MenB) GSK] and MenB-FHbp Trumenba, Pfizer Inc.), are licensed and available in the United States and have been recommended by CDC's Advisory Committee on Immunization Practices (ACIP).On October 20, 2023, the Food and Drug Administration approved the use of a pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp Penbraya, Pfizer Inc.) for prevention of invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y among persons aged 10-25 years.On October 25, 2023, ACIP recommended that MenACWY-TT/MenB-FHbp may be used when both MenACWY and MenB are indicated at the same visit for the following groups: 1) healthy persons aged 16-23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine, and 2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia).Different manufacturers' serogroup B-containing vaccines are not interchangeable; therefore, when MenACWY-TT/MenB-FHbp is used, subsequent doses of MenB should be from the same manufacturer (Pfizer Inc.).This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-TT/MenB-FHbp. * Nimenrix and MenQuadfi (both abbreviated MenACWY-TT) are different vaccines containing different amounts of tetanus toxoid conjugate.